Status:

NOT_YET_RECRUITING

"Transarterial Microembolization (TAME) in Inflammatory Knee Pathology"

Lead Sponsor:

Istituto Ortopedico Rizzoli

Conditions:

Inflammatory Articular Diseases

Knee Osteoarthristis

Eligibility:

All Genders

40+ years

Brief Summary

Patients with knee OA and chronic pain refractory to at least 3 months of conventional conservative therapy will be included in the study, which will evaluate the clinical results obtained after treat...

Detailed Description

Degenerative and inflammatory joint disease is a common and debilitating condition that causes pain and limited mobility, with osteoarthritis (OA) being the most common form. The knee is the most comm...

Eligibility Criteria

Inclusion

  • \- Patients with degenerative knee disease:
  • Age over 40 years;
  • Moderate knee OA (grade 2-3 according to the Kellgren-Lawrence score) for which an indication for total knee arthroplasty surgery has already been given;
  • Knee OA with an inflammatory component (night pain, pain at rest, recurrent episodes of effusion, swelling and/or redness);
  • Persistent and moderate or severe knee pain (VAS score \> 4);
  • Failure after at least 3 months of conservative therapies (e.g., physical therapy, drug therapy with NSAIDs and pain relievers, hyaluronic acid infiltration, corticosteroids, or orthobiologics).
  • Signature of informed consent
  • Case declared eligible for treatment following discussion at internal multidisciplinary meeting on degenerative-inflammatory disease

Exclusion

  • Mentally incompetent patients;
  • Patients with trauma in the 6 months prior to treatment;
  • Patients with malignant neoplasms;
  • Patients with rheumatic diseases;
  • Patients on anticoagulant-antiaggregant therapy (including if therapy can be discontinued 5 days earlier);
  • Patients abusing alcoholic beverages, drugs, or medications;
  • Patients undergoing surgery of the affected knee in the previous 12 months;
  • INR \<2;
  • Platelet count \<30,000;
  • Renal function: GFR\<30ml/min;
  • Pregnancy;
  • Allergy to iodinated contrast.
  • Ineligibility to perform MRI examination.

Key Trial Info

Start Date :

September 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2031

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT07140367

Start Date

September 1 2025

End Date

September 1 2031

Last Update

August 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IRCCS Istituto Ortopedico Rizzoli

Bologna, Bologna, Italy, 40136